Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:INSPNASDAQ:NARINYSE:NVRONASDAQ:SWAVNASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINSPInspire Medical Systems$128.39-1.8%$142.27$123.00▼$225.00$3.86B1.25551,519 shs301,417 shsNARIInari Medical$79.97$79.97$39.76▼$79.99$4.68B1.021.43 million shsN/ANVRONevro$5.85+0.1%$5.85$3.17▼$10.37$224.32M0.81797,136 shs753,602 shsSWAVShockwave Medical$334.75$332.85$157.00▼$334.90$12.57B0.88968,088 shsN/ATNDMTandem Diabetes Care$17.06-0.1%$20.55$15.75▼$48.24$1.14B1.481.48 million shs1.10 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINSPInspire Medical Systems-1.71%-1.23%-7.25%-9.26%-4.03%NARIInari Medical0.00%0.00%0.00%0.00%+59.91%NVRONevro0.00%0.00%0.00%0.00%-30.24%SWAVShockwave Medical0.00%0.00%0.00%0.00%0.00%TNDMTandem Diabetes Care-0.09%-10.71%-17.29%+1.09%-57.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINSPInspire Medical Systems4.8582 of 5 stars4.41.00.04.83.32.51.9NARIInari Medical0.4681 of 5 stars1.10.00.00.01.42.50.6NVRONevro0.1746 of 5 stars1.00.00.00.00.01.70.6SWAVShockwave MedicalN/AN/AN/AN/AN/AN/AN/AN/ATNDMTandem Diabetes Care4.3054 of 5 stars4.21.00.04.93.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINSPInspire Medical Systems 2.73Moderate Buy$211.9165.06% UpsideNARIInari Medical 2.14Hold$69.22-13.44% DownsideNVRONevro 1.92Reduce$5.36-8.29% DownsideSWAVShockwave Medical 0.00N/AN/AN/ATNDMTandem Diabetes Care 2.40Hold$33.4395.90% UpsideCurrent Analyst Ratings BreakdownLatest NVRO, SWAV, TNDM, NARI, and INSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025TNDMTandem Diabetes CareTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$24.005/22/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $24.005/6/2025INSPInspire Medical SystemsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$220.00 ➝ $200.005/6/2025INSPInspire Medical SystemsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$235.00 ➝ $195.005/6/2025INSPInspire Medical SystemsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$195.00 ➝ $174.005/6/2025INSPInspire Medical SystemsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$230.00 ➝ $236.005/1/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$58.00 ➝ $59.005/1/2025TNDMTandem Diabetes CareStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $31.005/1/2025TNDMTandem Diabetes CareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$22.00 ➝ $20.005/1/2025TNDMTandem Diabetes CarePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$36.00 ➝ $30.005/1/2025TNDMTandem Diabetes CareRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$33.00 ➝ $24.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINSPInspire Medical Systems$802.80M4.72$1.68 per share76.51$23.01 per share5.58NARIInari Medical$493.63M9.48$0.09 per share906.95$8.07 per share9.91NVRONevro$408.52M0.55N/AN/A$8.10 per share0.72SWAVShockwave Medical$787.97M15.95$4.31 per share77.61$20.02 per share16.72TNDMTandem Diabetes Care$940.20M1.21N/AN/A$4.01 per share4.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINSPInspire Medical Systems$53.51M$2.1759.1639.872.007.92%10.00%8.68%8/5/2025 (Estimated)NARIInari Medical-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/ANVRONevro-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%8/4/2025 (Estimated)SWAVShockwave Medical$147.28M$4.2878.2154.342.4320.75%24.79%11.95%N/ATNDMTandem Diabetes Care-$96.03M-$2.78N/AN/AN/A-18.71%-57.33%-13.48%8/6/2025 (Confirmed)Latest NVRO, SWAV, TNDM, NARI, and INSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025INSPInspire Medical Systems-$0.23$0.10+$0.33$0.10$194.89 million$201.32 million4/30/2025Q1 2025TNDMTandem Diabetes Care-$0.60-$0.67-$0.07-$1.97$220.19 million$234.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINSPInspire Medical SystemsN/AN/AN/AN/AN/ANARIInari MedicalN/AN/AN/AN/AN/ANVRONevroN/AN/AN/AN/AN/ASWAVShockwave MedicalN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINSPInspire Medical SystemsN/A9.017.44NARIInari MedicalN/A1.771.40NVRONevro0.675.023.76SWAVShockwave Medical0.9713.8112.61TNDMTandem Diabetes Care1.992.301.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINSPInspire Medical Systems94.91%NARIInari Medical90.98%NVRONevro95.52%SWAVShockwave Medical95.35%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipINSPInspire Medical Systems4.10%NARIInari Medical10.60%NVRONevro3.20%SWAVShockwave Medical3.40%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINSPInspire Medical Systems1,24629.49 million28.29 millionOptionableNARIInari Medical80058.54 million52.34 millionOptionableNVRONevro1,09038.37 million36.27 millionOptionableSWAVShockwave Medical1,46837.54 million36.27 millionOptionableTNDMTandem Diabetes Care2,65066.61 million65.34 millionOptionableNVRO, SWAV, TNDM, NARI, and INSP HeadlinesRecent News About These CompaniesTandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025 - MorningstarJuly 2 at 10:52 PM | morningstar.comMRSI Alert: Tandem Diabetes Care (TNDM) Now OversoldJuly 2 at 10:52 PM | nasdaq.comTNDM - Tandem Diabetes Care Inc Key Metrics - MorningstarJuly 1 at 10:47 PM | morningstar.comMTandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025July 1 at 4:05 PM | businesswire.comTandem Diabetes Care (NASDAQ:TNDM) Shares Gap Down - Here's WhyJuly 1 at 12:35 PM | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives $33.43 Consensus Price Target from BrokeragesJune 28, 2025 | americanbankingnews.comTNDM - Tandem Diabetes Care Inc Financials - MorningstarJune 27, 2025 | morningstar.comMThe 5 Most Interesting Analyst Questions From Tandem Diabetes’s Q1 Earnings CallJune 27, 2025 | msn.comTNDM | Tandem Diabetes Care Inc. Annual Cash Flow Statement - MarketWatchJune 26, 2025 | marketwatch.comTandem Diabetes Care (NASDAQ:TNDM) Shares Down 5.9% - Time to Sell?June 25, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Recommendation of "Hold" by BrokeragesJune 25, 2025 | marketbeat.comTandem Diabetes Care Inc TNDM Company Vitals - U.S. NewsJune 24, 2025 | money.usnews.comTNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3June 24, 2025 | msn.comTNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3 +June 23, 2025 | zacks.comTandem continues to deliver more options, benefits for those with diabetesJune 22, 2025 | massdevice.comTandem Diabetes Care (NASDAQ:TNDM) Stock Rating Lowered by Wall Street ZenJune 21, 2025 | marketbeat.comStudy backs Tandem automated insulin delivery in pregnant women with type 1 diabetesJune 20, 2025 | drugdeliverybusiness.comDTandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.June 20, 2025 | drugdeliverybusiness.comDTandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott’s FreeStyle Libre® 3 Plus Sensor in the United StatesJune 20, 2025 | uk.finance.yahoo.comTandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott's FreeStyle Libre® 3 Plus Sensor in the United StatesJune 20, 2025 | businesswire.comChicago Capital LLC Has $397,000 Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)June 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeIs Lululemon’s 18% Selloff Overdone? Analysts Say YesBy Gabriel Osorio-Mazilli | June 9, 2025View Is Lululemon’s 18% Selloff Overdone? Analysts Say YesNVRO, SWAV, TNDM, NARI, and INSP Company DescriptionsInspire Medical Systems NYSE:INSP$128.38 -2.34 (-1.79%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$128.38 0.00 (0.00%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.Inari Medical NASDAQ:NARI$79.97 0.00 (0.00%) As of 02/19/2025Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.Nevro NYSE:NVRO$5.85 +0.01 (+0.10%) Closing price 04/2/2025Extended Trading$5.85 0.00 (0.00%) As of 04/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.Shockwave Medical NASDAQ:SWAVShockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.Tandem Diabetes Care NASDAQ:TNDM$17.06 -0.02 (-0.09%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$16.72 -0.34 (-2.02%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
